Instruction for use: MadoparI want this, give me price
Dosage form: capsules
Active substance: Levodopa + Benserazide*
N04BA Dopa and its derivatives
Dopaminomimetics in combinations
Antiparkinsonics in combinations
The nosological classification (ICD-10)
G20 Parkinson's disease: A trembling paralysis; Idiopathic Parkinsonism; Parkinson's disease; Symptomatic Parkinsonism
G21 Secondary Parkinsonism: Medicinal Parkinsonism; Parkinsonism; Parkinsonism symptomatic; Disorders of extrapyramidal system; Parkinson's Syndrome
Composition and release form
1 capsule contains levodopa 100 mg and benserazide (as chloride) 25 mg; In a glass jar 100 pcs., In a box of 1 can.
The pharmacological action is antiparkinsonian.
Increases the content of dopamine in the central nervous system (levodopa) and reduces hypokinesia, rigidity, tremor; Inhibits peripheral decarboxylase (benserazide), reducing the accumulation of dopamine outside the central nervous system.
Indications of the Madopar
Parkinson's disease, symptomatic parkinsonism (with the exception of medication).
Diseases of the endocrine system, kidneys, liver, heart, psychosis, pregnancy, age (under 25 years).
Insomnia, a sense of anxiety, depression, choreal and lethargic movements; In rare cases - leukopenia, thrombocytopenia.
Dosing and Administration
Inside. The dose is selected individually.
At the beginning of treatment, one should not abruptly discontinue the use of other antiparkinsonian drugs. It is not recommended to combine with MAO inhibitors. With prolonged use, it is necessary to monitor the blood picture, kidney and liver function
Storage conditions of the drug Madopar
Keep out of the reach of children.
Shelf life of the drug Madopar
Do not use after the expiry date printed on the package.